01 / UNIQUELY
02 / DEPENDABLY
03 / EASY
04 / SPEEDY
A highly innovative approach has been optimized for efficient generation, selection, and expansion of high affinity monoclonal antibodies with neutralizing activity and unique amino acid structure. A fully human antibody could significantly reduce potential immune responses, as compared to antibody therapeutics that contain nonhuman components.
Our technology allows to detect and generate different specific high-affinity fully human antibodies for antibody-based therapy and diagnosis. In addition to cancer treatment many other conditions effectively treated by an ILGEN's human antibodies could include infections, rheumatic and autoimmune diseases, vascular and lymphoproliferative disordes. ILGEN has patent application.
The therapeutic or diagnostic fully human antibodies and fusion proteins of the present technology are those derived from human tissues with further possibility to be purified, scale-up produced appropriate quantities and used in treatment or diagnosis of human diseases as pharmaceutical agents.
Advantage of our approach is a significant reduction in turnaround time. It typically takes 1-2 years to obtain functionally validated and sequenced antibodies using traditional hybridoma and humanization methods or phage libraries. In contrast, it would take no more than 6 months using our approach.
TECHNOLOGY AND HUMAN ANTIBODIES
Development of our technology will allow to detect and generate different fully human antibodies for antibody-based therapy and diagnosis.
The technology is protected by patent (US Patent 9810694).
Anti-LAG-3 antibody is a fully human antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities.
The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered interest in this treatment approach.
Anti-LAG-3 antibody is a new generation of therapeutic immune checkpoint inhibitors.
HUMAN FUSION PROTEIN ILG-F
This project leverages a highly innovative approach for generating fully human fusion protein ILG-F for the treatment of the men with erectile dysfunction (ED).
More than 50% of men with ED have vasculogenic ED (cavernosal artery insufficiency). PDE5 inhibitors (Viagra, etc.) have no effects on endothelium formation and revascularization. Novel fully human fusion protein ILG-F could stimulate revascularization and impact on dysfunction of the cavernosal endothelial cells.
Abstract of ILGEN "Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor" has been selected for presentation in a poster session at the 2019 ESMO Congress in Barcelona (Spain).
Abstract of ILGEN "Naturally circulating anti-LAG3 antibodies exist in cancer patients" has been selected for presentation in a poster session at the 2019 AACR Annual Meeting in Atlanta (USA).
New data demonstrating activation of the immune system by an ILGEN's antibody produced by a new technology will be presented as a poster at the AACR-NCI-EORTC international conference on Molecular targets and Cancer Therapeutics
Date and time: 12 October 2023, 12:30-16:00
Location: Poster session A, Hynes Convention Center, Boston, MA